Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences

BACKGROUND: Despite recent approvals of lifesaving treatments for chronic lymphocytic leukemia (CLL), real-world data on the tolerability of the Bruton tyrosine kinase inhibitor ibrutinib for CLL treatment are lacking, especially in Black patients. OBJECTIVE: To expand upon a previously reported ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrientos, Jacqueline C., Ayed, Ayed O., Cha, Agnes, Du, Senxi, Fang, Bruno, Hall, Ryan, Marks, Stanley M., Peng, Eileen, Rhodes, Joanna M., Ryan, Kellie, Winters, Sharon B., Yeung, Percy L., Hou, Jing-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517886/
https://www.ncbi.nlm.nih.gov/pubmed/37728835
http://dx.doi.org/10.1007/s11523-023-00988-0

Ejemplares similares

Ejemplares similares